Browse All

Current Filters

CLEAR FILTER x

TITLE

Occipital Nerve Block with Lidocaine for Acute Post-stroke Headache: Preliminary Results

Author:Zeldich, Dean   Shabo, Leah   Steinberg, Deborah   Marmura, Michael   Mittal, Shilpi   

Session Name:P1: Headache: Nerve Blocks and Non-pharmacological Approaches in Headache Medicine  

Topic:Headache  

Program Number:P1.020  

Author Institution:Thomas Jefferson University Hospital, Philadelphia, PA  Thomas Jefferson University Hospital , Philadelphia, PA  Thomas Jefferson University, Philadelphia, PA  

Occipital Pain as a Symptom of Multiple Sclerosis: Prevalence, Clinical Subtypes, and Association With Upper Cervical Spinal Cord Demyelination

Author:Albites Coen, Bianca   Kissoon, Narayan   Chowdhury, Purnashree   Keegan, Mark   

Session Name:P4: Multiple Sclerosis: Clinical Science 1  

Topic:Multiple Sclerosis  

Program Number:P4.007  

Author Institution:Mayo Clinic, Rochester, MN  Mayo Clinic, Chattogram, Bangladesh  

OCT-derived Retinal Measures Correlate With Brain-predicted Age, Neurodegeneration, and Disease Progression in Multiple Sclerosis

Author:Nourelden, Anas   Bao, Fen   Liaquat, Zaima   Santiago-Martinez, Carla   Memon, Anza   

Session Name:P4: Multiple Sclerosis: Digital Health, Biomarkers, and Artificial Intelligence 1  

Topic:Multiple Sclerosis  

Program Number:P4.006  

Author Institution:Wayne State University, School of Medicine, Detroit, MI  John D. Dingell, VAMC  

Ocular Manifestations Among Anti-IgLON5 Patients

Author:Ismail, Muhammad   Bao, Fen   Elkhooly, Mahmoud   

Session Name:P1: Autoimmune Neurology: Central Nervous System 1  

Topic:Autoimmune Neurology  

Program Number:P1.010  

Author Institution:Minia University , Minia, Egypt  Wayne State University , Detroit, MI  Southern Illinois University , Springfield, IL  

Ofatumumab Treatment Up to 8 Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Montalban, Xavier   Cohen, Jeffrey   Morrow, Sarah   Li, Jun   Carr, David   Pearce, Gregory   Solonets, Maria   Abeyewickreme, Anil   de Seze, Jérôme   Nakahara, Jin   Wiendl, Heinz   Hauser, Stephen   

Session Name:P9: Multiple Sclerosis: Clinical Trials 2  

Topic:Multiple Sclerosis  

Program Number:P9.006  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Department of Neurology/Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, calgary, AB, Canada  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  IQVIA RDS GmbH, Frankfurt, Germany, Germany  Novartis Pharmaceuticals UK Ltd, London, United Kingdom, London, United Kingdom  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Klinik für Neurologie und Neurophysiologie, Universitätsklinikum Freiburg, Freiburg, Germany, Freiburg im Breisgau, Germany  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA